Mark Corrigan is a Strategic Advisor and a recognized leader in life sciences. He has led strategic turnarounds and mergers and is unabashedly driven by a passion to create new medicines and bring them successfully to market. Mark spent a decade at Pharmacia rising to Group VP for Clinical Research and Experimental Medicine. He then joined Sepracor as CSO of Research and Development and following a successful merger with Dainippon Sumitomo, took his first CEO position at Zalicus. Subsequently, Dr. Corrigan co-founded a rare diseases company, Tremeau Pharmaceuticals and following its acquisition, he assumed the leadership of Correvio Pharma, a publicly traded, global, commercial stage company. Dr. Corrigan has extensive Board experience in research, clinical and commercial stage companies where he has served as Chairman and Executive Chairman.
Mark received his MD at Univ. Virginia, residency training in psychiatry and appointment to the faculty of the University of North Carolina.